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Previous research has found omega-3 fatty acid supplementation 
advantageous in reducing depressive symptoms. One of the central diagnostic 
symptoms of depression is sleep disturbance. Accordingly, this study was designed 
to examine the effects of omega-3 fatty acid on self-reported insomnia.  It was 
hypothesized that participants assigned to supplement their diet with omega-3 fatty 
acid would have improvements in sleep efficiency, sleep onset latency, sleep 
fragmentation and actual sleep time. Supplementary hypotheses examined were that 
omega-3 fatty acid might improve cognitive ability and sub-syndromal depressive 
symptoms. Participants were 27 undergraduate students reporting a variety of sleep 
difficulties as assessed by self report of insomnia symptoms. Participants were 
randomly assigned either to a treatment condition, with a daily supplement of 1500 
mg omega-3 fatty acid and 30 IU of vitamin E, or a control group that received 30 IU 
daily of vitamin E. Sleep was monitored over a 28 day period, the last 21 days of 
which participants were instructed to take the assigned supplements.  Participants 
were measured on objective (Actigraph) and subjective self-report measures of sleep 
for seven days prior to the intervention, and during the last seven days of the 
intervention. They also completed a self-report screen for depressive symptoms and 
several cognitive tasks immediately prior to and following the intervention. A 2x2 
mixed factoral analysis of variance was performed on all outcome variables. The 
treatment group did not improve significantly more than the control group on any 
measures of sleep, or mood. One cognitive measure of processing speed did 
significantly improve for the treatment condition.  These findings are discussed in 
light of study limitations and the existing literature, and recommendations made for 
additional research focused on the possibility of sleep improvements with omega-3 








Omega-3 Fatty Acid Supplementation and Sleep 
 
Omega-3 fatty acid supplementation has recently gained considerable media 
attention for its potential efficacy in addressing a broad array of adverse health 
conditions.  In fact, there exists published empirical evidence that it may be a useful 
intervention for serious medical conditions ranging from atheroscleroris (von 
Schacky, Angerer, et al, 1999) rheumatoid arthritis (Geusens, Wouters, Nijs, et al, 
1994; Kjeldsen-Kragh, Lund, et al, 1992) hypertriglyceridemia (Wohl, Tien, et al, 
2005) high blood pressure (Sacks, Hebert, et al, 1994) and skin conditions like 
eczema and psoriasis (Calder & Miles, 2000).  Accordingly, the American Heart 
Association (AHA) has recently published a comprehensive list of medical uses for 
omega-3 fatty acids, and a rating system for their use based on empirical evidence of 
their likeliness to improve health. The AHA has also supported the use of omega-3 
fatty acids for prevention of heart disease at a dosage of 1-3 grams.  (Albert, 
Kyungwon, & Wang, 2004).   
Omega-3 fatty acids are synthesized by plants, but they are acquired by 
humans through the consumption of animals which have eaten plants – especially 
grasses and algae – that contain omega-3s. There are three distinct molecular 
varieties of omega-3 fatty acids: alpha-linolenic acid (ALA), eicosapentaenoic acid 
(EPA), and docosahexaenoic acid (DHA).  ALA has been shown to be essential for 
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heart and cardiovascular health, while DHA, a key constituent of the neural 
membrane, has been found to be important for brain growth and development 
(Parker, Gibson, et. al, 2006; Peet, 2003), and EPA has been shown to improve the 
overall efficiency of neural function (Logan, 2003).  Dietary omega-3 deficiency has 
even been identified as a key vulnerability factor regarding the global burden of 
disease, including unipolar depression and bipolar disorder (Hibbeln et al, 2006). 
 Relevant epidemiological studies suggest that omega-3 fatty acids used to be 
much more prevalent in the human diet than they are today (Parker, Gibson, et. al, 
2006; Peet, 2003).  The contemporary deficiency appears to reflect the fact that meat 
products consumed today are no longer derived from naturally grazing animals – i.e., 
animals that consume the plants that contain omega-3 fatty acids. It is important to 
note in this context that humans cannot directly take in and digest the long-chain 
molecular versions of omega-3 fatty acid (EPA and DHA) in plant form.  In order for 
humans to most efficiently consume EPA and DHA, they must ingest animals that 
have consumed these molecules in plant form. Animal meats and animal products are 
thus the richest potential sources of human-usable EPA and DHA (Parker, Gibson, 
et. al, 2006; Peet, 2003). 
Examination of the list of potential uses for omega-3 fatty acids reveals a 
common factor across several of the diseases previously mentioned: they are all 
characterized by inflammation. This fact has led to an investigation of the 
mechanisms – including a robust anti-inflammatory effect (Tiemeier et al, 2003; 
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Edwards et al, 1998; Peet et al, 1998) – by which omega-3 fatty acid intake may 
improve such conditions. 
 Interestingly, major depressive disorder is also characterized by elevated 
inflammation (Glassman & Miller, 2007; Leonard, 2007; Sluzewska, Rybakowski, et 
al, 1996; Kenis & Maes, 2002), and individuals experiencing depression have 
significantly lower levels of omega-3 fatty acids present in adipose tissue and 
circulating blood plasma (Tiemeier et al., 2003; Maes et al., 1996; Edwards et al., 
1998; Peet et al., 1998). Supplementation of omega-3 fatty acids in depressed 
individuals also results in a statistically significant improvement in depressive 
symptoms (Nemets et al, 2002; Peet & Horrobin, 2002), one of which is disordered 
sleep.  Sleep difficulties, including sleep disruption, altered sleep architecture, and 
overall non-restful sleep, are central symptoms of major depressive disorder, and up 
to 90 percent of depressed individuals also experience adverse changes in sleep 
(Thase, 1999).   
 It has recently been estimated that 58 percent of the American adult 
population experiences at least occasional difficulties with sleep (Gelula, 2002).  
Accordingly, considerable research effort has been directed at the development of 
effective interventions for insomnia and other sleep disorders.  Inasmuch as omega-3 
supplementation is capable of reducing depressive symptomatology – including 
disordered sleep – it is possible that such supplementation may have potential as an 
intervention for sleep disturbance, even among non-depressed individuals.  This 
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hypothesis has not yet been explicitly investigated, but there is evidence for 
regarding it as plausible. 
How omega-3 fatty acids may influence sleep 
The Hypothalamic-Pituitary-Adrenal Axis and Inflammation 
As noted above, omega-3 fatty acids are anti-inflammatory, and this anti-
inflammatory effect has a regulatory effect on the hypothalamic-pituitary-adrenal 
(HPA) axis. The HPA axis is an important part of the stress response system, and 
also plays a critical role in sleep.  Because chronic inflammation in the body over-
activates the HPA axis, it can in turn damage sleep quality and quantity. 
 By introducing omega-3 fatty acids into the body, inflammation can be 
decreased (Calder, 2002; Simopoulos, 2002; Motivala, Sarfatti, et al., 2005) and 
various studies have shown that omega-3 fatty acids inhibit chronic inflammatory 
responses (Calder, 2002). When inflammation is controlled, pro-inflammatory 
cytokines are no longer circulating in high quantities. Such cytokines, measurable 
markers of inflammation, also activate the stress response in the hypothalamic-
pituitary-adrenal (HPA) axis, an event that can promote sleep disruption. Poor sleep 
has been linked to increases in circulating cytokines, providing evidence for a cycle 
of chronic inflammation and sleep difficulties.  
There are multiple lines of evidence which suggest that increased 
inflammation, especially chronic inflammation, is associated with sleeping 
difficulties (Mullington, Hinze-Selch, et al, 2001; Song, et al, 1998). Also, 
inflammation can alter sleep architecture and sleep disturbances can, in turn, impair 
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immune functions (Song, et al, 1998). This promotes a vicious cycle of poor sleep 
contributing to disregulated immune function, which again leads to poor sleep. It is 
hypothesized that omega-3 fatty acids may be able to break this cycle by decreasing 
inflammation, and thus inhibiting the runaway immune-inflammation response and 
its deleterious effect on sleep.  
A prominent theory of sleep disorders involves disregulation of the body’s 
stress response system, particularly the hypothalamic-pituitary-adrenal axis (HPA 
axis) and its components. One of the important functions of the HPA axis is to 
maintain alertness and to regulate sleep (Buckley & Schatzberg, 2005). When the 
HPA axis is dysregulated it can cause disruption of sleep, and hyper-activity of the 
HPA axis can cause problems with various stages of sleep (Buckley & Schatzberg, 
2005).  
Elaboration on the effect of inflammation on the HPA axis is necessary to 
fully understand how omega-3 fatty acids may influence sleep. The HPA axis is 
structurally composed of the hypothalamus, the pituitary gland, and the adrenal 
gland. The hypothalamus signals the pituitary gland by way of a neurohormone, 
corticotrophin-releasing hormone (CRH), while the pituitary gland sends signals to 
the adrenal gland via a different neurohormone, adrenocorticotropin (ACTH). When 
an individual is exposed to a stressor, the hypothalamus produces CRH, which then 
triggers the release of ACTH, which is released into the bloodstream and travels to 
various systems throughout the body.  The target location of importance in this study 
is the adrenal gland, which triggers the release of cortisol.  
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Corticotrophin releasing hormone (CRH), regulated by the hypothalamus, 
causes the HPA axis to become more active. Not surprisingly, an increase in 
circulating CRH increases wakefulness (Buckley, and Schatzberg, 2005) and in a 
study of healthy adult males without sleep disorders, CRH decreased slow wave 
sleep while increasing light sleep and wakefulness (Holsboer, von Bardeleben, and 
Steiger, 1988).  CRH can be produced in response to stress, as well (Buckley, and 
Schatzberg, 2005). This begins a cycle of changes that result in chronic sleep 
problems. As excessive CRH hyper-activates the HPA axis, sleep is disturbed. The 
body becomes less capable of regulating the stress response in the future, which in 
turn lends itself to the cycle being replicated, with the HPA axis operating at a 
consistent level of hyperactivity.  
ACTH activity is also of particular interest, as activation of the adrenal gland 
by ACTH triggers the release of glucocorticoid stress hormones (Lambert, K. and 
Kinsley, C.H., 2005). The glucocorticoid most relevant to the HPA axis function and 
sleep is cortisol. In a healthy HPA axis response, cortisol is the neurohormone 
critical to the deactivation of the HPA axis stress response. When cortisol does not 
effectively deactivate the HPA axis, hyper-activation occurs. Hyper-activation of the 
HPA axis is connected with depression, sleep difficulties, and anxiety (Lambert, K., 
and Kinsley, C.H., 2005). The HPA axis can also be hyper-activated by prolonged 
stress, and as mentioned, chronic inflammation in the body, which produces 
cytokines that continue to activate the release of CRH in the hypothalamus. When 
the body’s inflammation response is appropriately regulated, it is hypothesized that 
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hyper-activation of the HPA axis can be decreased. Omega-3 fatty acids have strong 
anti-inflammatory effects in the body, and thus may reduce activation of the HPA 
axis. 
Adequate and homeostatic levels of cortisol are imperative for brain and body 
functioning because it regulates glucose metabolism, blood pressure, insulin release, 
immune responses, and inflammatory functions (Brown, 2004). A chronic excess of 
circulating cortisol has myriad potential for negative effects in the body, such as 
impaired cognitive performance, decreased thyroid function, hyperglycemia, 
decreases in bone density and muscle tissue, high blood pressure, lowered immunity, 
increased abdominal fat, and increased heart attack and stroke susceptibility (Brown, 
2004).  
Cortisol is also influential in the sleep cycle. Cortisol levels fluctuate across 
the various stages of sleep and wakefulness. Most research examining the influence 
of cortisol on sleep has focused on its contribution to sleep disruption. Waking at 
night has been associated with spikes in the release of cortisol (Follenius, 
Brandenberger, et al, 1992; Spath-Schwalbe, Gofferje, et al, 1991). Research has also 
confirmed that chronic insomnia, even in the absence of depression, is associated 
with elevated cortisol levels (Rodenbeck, Hajak, 2001; Rodenbeck, Huether, et. al, 
2002; Vogntzas, Tsigos, et al, 1998; Vgontzas, Bixler, et al, 2001). Research has also 
suggested that elevated cortisol levels may just be related to increased CRH activity 
as well (Buckley & Schatzberg, 2005). Cortisol levels from the evening before sleep 
also correlate with the number of nocturnal awakenings in both individuals with and 
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without insomnia (Rodenbeck, Hajak, 2001; Rodenbeck, Huether, et. al, 2002). 
There is sufficient literature to determine that non-homeostatic levels of circulating 
cortisol contribute to sleep difficulties. A large influence on non-homeostatic levels 
of cortisol is directly related to the disregulation of the HPA axis.  
Chronic stressors contribute to the hyper-activation of the HPA axis. One 
mechanism in this regard is inflammation. Prolonged hyper-activation of the HPA 
axis leads to non-homeostatic levels of the glucocorticoid cortisol. The over-
abundance of cortisol, in turn, contributes to repeated activation of the HPA axis; 
thus, a cycle is created in which the HPA axis cannot be properly regulated. Through 
research in the area of depression, it has been documented that markers of 
inflammation (cytokines) increase with exposure to chronic stressors as well as 
chronic sleep problems. These cytokines also activate the HPA axis. Thus, it is 
hypothesized that a vicious cycle may ensue, in which stress induces both HPA axis 
activation and excessive inflammation, which in turn contribute to the onset of sleep 
problems, which exacerbates stress, and so on.  
In conclusion, HPA axis hyper-activity can lead to sleep fragmentation, 
shortened time spent in restorative slow wave sleep, and less time engaged in sleep. 
At the same time, sleep disturbances can make HPA axis dysfunction intensify. It is 
hypothesized that HPA axis hyper-activity is mediated by persistent release of CRH, 
which in turn signals non-homeostatic release of cortisol (Rodenbeck, Hajak, 2001; 
Rodenbeck, Huether, et. al, 2002), both of which have deleterious effects on the 
negative feedback loop that “turns off” CRH production in the HPA axis. It is further 
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hypothesized that increased CRH production may be due to high levels of pro-
inflammatory cytokines in the bloodstream (Buckley & Schatzberg, 2005). Omega-3 
fatty acids are likely to manage inflammation in the body so as to prevent a runaway 
cycle of inflammation that can damage sleep and thereby perpetuate further 
inflammation and thus further sleep difficulties. 
In the case of sleep disorders and depression, as well as other disorders, a 
decrease in HPA axis hyper-activity results in decreased symptomatology. It is 
hypothesized that since omega-3 fatty acid has been shown in some studies to be 
efficacious in treating depression through possibly the same regulatory mechanism, 
that omega-3 fatty acid may also alleviate sleep difficulties. 
Possible Benefits of Omega-3 Fatty Acids 
Omega-3 fatty acid has been shown to have an effect on the HPA axis via the 
same mechanism through which they control inflammation. The pro-inflammatory 
cytokines activate the HPA axis by activating the release of CRH (Buckley & 
Schatzberg, 2005). Omega-3 fatty acids decrease the level of pro-inflammatory 
cytokines circulating in the body by binding to sites in the central nervous system 
that would otherwise be bound with Omega-6 fatty acids. Omega-6 fatty acids 
generally promote inflammation by serving as precursors for the production of pro-
inflammatory hormones (eicosanoids).   However, the typical American diet contains 
more omega-6 faty acids, which leaves omega-6 fatty acids more available for the 
body’s use. By making more omega-3 fatty acid available, the body is able to use 
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omega-3 fatty acids before resorting to omega-6 fatty acids.  Omega-3 fatty acids are 
more efficient and have less negative inflammatory effects (Taperio, Ba, et al, 2002). 
The hypothesized mechanisms by which omega-3 fatty acids may mediate 
the amelioration of sleep disturbances are not directly investigated in this study.  
Before such mechanisms can be investigated, it is useful merely to demonstrate that 
omega-3 fatty acid supplementation is an intervention that has a beneficial effect on 
sleep.  Although there are some existing published studies that have reported 
beneficial sleep changes associated with omega-3 supplementation, these studies 
have mainly focused on changes in affect, with sleep examined only tangentially as a 
part of a battery assessing depressive or manic symptoms or learning and behavior 
problems (Stevens, Zentall, et al, 1996; Sorgi, Hallowell, et al, 2007).  
Nevertheless, there is reasonable evidence to support the hypothesis that 
omega-3 fatty acid may help ameliorate sleep abnormalities.  The primary aim of the 
present study was to examine this hypothesis, utilizing a supplemental omega-3 dose 
(1000mg of EPA and 500mg DHA daily) that has been supported as efficacious in 
addressing depressive symptoms, including sleep abnormalities (Kiecolt-Glaxer, 
Belury, et al, 2007; Peet & Horrobin, 2002).  Specifically, supplement-related 
changes in nightly sleep quantity and quality will be assessed by means of 
continuous Actiwatch/Actigraph monitoring, in tandem with daily sleep diaries, 
among a sample of 27 undergraduates selected on the basis of self-reported sleep 
disturbance. 
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  There is also substantial evidence to indicate that improved sleep can 
enhance cognitive performance (Randazzo, Muehlbach, et al., 1998; Ohayon, 
Vecchierini, 2005; Borak, Cieslicki, et al., 1996).  Moreover, the effects of omega-3 
fatty acid supplementation on cognitive function have also been examined with 
promising results (Kalmijn, van Boxtel, et al., 2004; Kalmijn, Launer, et al., 1997; 
Richardson, and Puri, 2002; Stevens, Zentall, 1995).  Accordingly, the present study 
also examined the auxiliary hypothesis that cognitive function – specifically, 
attention, working memory, attentional flexibility, visual conceptual/visiomotor 
tracking, immediate memory, processing speed, and recall ability– may improve as a 





 Participants were 27 individuals with self-reported symptoms of sleep 
disturbance (52% female) as evaluated by an online survey of introduction to 
psychology students at a large Midwestern university. The mean age of participants 
was 19.9 years (SD = 2.81). The majority were Caucasian (78 %). Their average 
body mass index (BMI) was 23.5 (SD=2.7), calculated using the standard body mass 
index formula. See Table 1 for characteristics of treatment and control group 
participants.  All subjects completed a medical history questionnaire prior to 
entrance into the study to ensure the absence of physical conditions (e.g., a blood 
clotting disorder) for which omega-3 fatty acid or vitamin E would be 




 Participants were selected from an introductory psychology class. Students 
from this class were required to participate in research as a requirement of course 
completion. Participants completed an initial screen for insomnia online (see 
appendix for screening questions) were invited to participate in the study via email. 
In order to qualify for participation, participants had to report that there sleep was not 
restful, that they experienced feeling tired during the day to the point where it made 
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it difficult to complete tasks at work, school, or at home. They also had to endorse 
experiencing one of the following three sleep disturbances at least 5 or more nights 
of the week: having difficulty falling asleep, having difficulty staying asleep, or 
waking early in the morning and not being able to fall back to sleep.  Prior to the 
study, all subjects were informed in detail about the investigation, the measures 
being collected, and the requirements they would need to meet, and gave their 
informed written consent. The study protocol was approved by the relevant 
institutional review board. 
Contact with participants occurred in a psychological laboratory on campus; 
this included completion of the consent process and all further screening procedures. 
Eligibility was confirmed after participants completed a medical history form to rule 
out possible contraindications for omega-3 fatty acid or vitamin E supplementation. 
After eligibility was determined participants completed a survey, the Pittsburg Sleep 
Quality Index (PSQI), to assess sleeping habits, the Beck Depression Inventory-II 
(BDI-II), and four cognitive tasks (Letter-Number Sequencing, the Rey Auditory and 
Verbal Learning Test [RAVLT], Trails A and B, and the Stroop test). Finally, they 
were be given a device called an Actigraph/Actiwatch, which was worn on their non-
dominant hand for the next 7 days. They were also instructed to fill out two sleep 
logs; (a) a sleep diary (National Sleep Foundation, 2005), and (b) a measure 
examining sleep and emotions (Buysse, Ancoli-Israel, et al., 2006).  At the end of the 
designated 7 days, participants returned to the lab to give back the watch in exchange 
for their assigned supplements (either vitamin E, or omega-3 fatty acid and vitamin 
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E). Participants were randomly assigned to a control or treatment condition prior to 
their arrival for the first session. The control condition was assigned to take a 30IU 
pill of vitamin E each day, while the treatment condition received 30 IU of vitamin E 
and approximately 1500mg of omega-3 fatty acid daily (in the form of 5 pills). In 
summary, the control condition took 1 pill a day (30IU vitamin E) and the treatment 
condition took a total of 6 pills (5 pills omega-3 fatty acid and 1 pill vitamin E). 
Participants were instructed to take the pills for the remainder of their time in the 
study (21 days) and encouraged to take them just prior to bedtime. On the last 7 days 
of the ensuing 21-day period, the participant wore the Actiwatch/Actigraph again. 
Upon the completion of the study, participants returned to the laboratory to return the 
watch, turn in 28 days’ worth of sleep diaries, and again complete the same cognitive 
tests administered before the intervention; the Beck Depression Inventory, and 
Pittsburgh Sleep Quality Index. 
 
Omega-3 fatty acid and vitamin E administration   
To control for the different supplements participants received based on their 
assigned group, all supplements were given in unmarked containers. The pills 
themselves look similar, inasmuch as both are gel caps of the same color and shape. 
Size is the only immediately apparent difference between the treatment and control 
supplements, with the omega-3 fatty acid supplement pills being approximately 3 
times larger than the vitamin E supplement. Participants were asked to indicate each 





 The primary objective method of measuring sleep behavior was the data 
collected using actigraphy. The actigraph is a piece of technology that looks much 
like a normal wristwatch, which is used to measure body movement. There are 
accelerometers within the watch, which measure and collect data regarding 
movement of the user. (Littner, M. et al, 2003). Data is gathered about the wearer’s 
activity level throughout the day. Data gathered by the watch is then downloaded on 
to a computer and analyzed to give estimates regarding various indicators of sleep 
elements (Littner, M. et. al, 2003). The theory for examining the data is based on the 
principal that there is less movement during sleep than when an individual is awake. 
(Littner, M. et. al, 2003). By looking at this information it is possible to determine 
sleep onset, wakenings, the quality of sleep, and duration of the sleep period.  
Regarding psychometric properties, it has been shown to be an efficient, economical, 
and adequate measure of sleep (Littner, M. et al, 2003). The actigraph device was 
worn on the non-dominant hand throughout the specified duration of the study. Data 
collected by the actigraph regarding body movement is a good indicator of sleep 
quantity, quality, and architecture (Littner, M. et al, 2003). Factors measured by the 
actigraph technology include sleep onset latency, actual sleep time, the number of 
wake bouts during sleep, the number of minutes moving during sleep, and a 
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calculation of sleep efficiency. Accordingly, data collected from the actigraph is an 
objective way of monitoring relevant sleep processes.  
In this study overall sleep efficiency was measured by the “Sleep Efficiency” 
score produced by the actigraph algorithm. Sleep onset was measured by the “Sleep 
Latency” score, actual sleep time was measured by the “Actual Sleep Time” score, 
also produced by an actigraph algorithm, and an objective estimate of awakening 
during sleep periods was determined by the “Number of Wake Bouts” score and 
supplemented with the “Number of Minutes Moving” score, also produced by the 
actigraph algorithm. 
Pittsburgh Sleep Quality Index 
The Pittsburgh Sleep Quality Index (PSQI) was administered to each 
participant at study entry and termination to assess sleep during the preceding month. 
It assesses subjective quality of sleep as well as subjective report of typical sleeping 
patterns, including typical bedtime, what time the participant gets up in the morning, 
an estimate of how long it takes them to fall asleep, as well as possible reasons for 
waking during sleep. A total PSQI score is generated from the responses and has 
been found to be a reliable and valid measure of subjective sleep disturbance 
(Backhaus, Junghanns, et al, 2002). A total PSQI score of 5 or greater is indicative of 
significant sleep disturbance (Buysse, Reynolds, et al, 2000). 
National Sleep Foundation Sleep Diary 
Participants completed the National Sleep Foundation (NSF) Sleep Diary 
(Buysse, Ancoli-Israel, et al, 2006) for every day they were in the study. The NSF 
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sleep diary was used to acquire the participant’s subjective experience of sleep for 
the duration of the study. It generates information regarding bedtime, wakenings, 
duration of sleep, medication taken, exercise, subjective restfulness of sleep, and 
alcohol and caffeine use. Sleep efficiency was calculated by dividing the estimated 
hours of sleep by the estimated time in bed. Sleep latency and number of awakenings 
were determined by the participant’s estimates recorded in the sleep diary. 
 
Cognitive Functioning 
 All cognitive tests were administered on the initial visit to the laboratory and 
the debriefing session on the last day of the experiment.  
Letter-Number Sequencing 
Letter-Number Sequencing, a subtest from the Wechsler Adult Intelligence 
Scale-III (WAIS-III) was administered to examine attention and working memory 
(Crowe, S.F., 2000; Wechsler, 1997). The administrator reads a list of letters and 
numbers to the participant. The participant then mentally reorganizes the list of 
letters and numbers and must recall the list back to the examiner with numbers 
repeated first in order followed by the letters, also in alphabetical order (see 
appendix). Participants start with a list of just two stimuli to reorganize and repeat 
and the list gets progressively harder pending the success of the participant on the 
subsequent administrations. 
Trails A and B 
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Trails A and B was used to assess visual conceptual and visuomotor tracking 
as well as processing speed. Participants are timed on how quickly they can draw 
lines in between numbers, searching in numerical order. Trails B is more difficult, 
for it requires participants to trace both letters and numbers in order. For example, 
the participant will draw a line from “1 to A to 2 to B, and so on”. Trails A and B 
have been found to be valid (Gaudino, E.A., Geisler, M.W. & N. K. Squires, 1995) 
but there are practice effects that make reliability difficult to assess (Fals-Stewart, W, 
1992). 
Rey Auditory and Verbal Learning Test 
The Rey Auditory and Verbal Learning Test (RAVLT) were used to assess 
immediate memory, effects of interference, and recall ability (Mungas, D, 1983).  
The first list is read and participants repeat back as many words as they can 
remember from the list. Then a second similar interference list is read and 
participants repeat back words they can remember. After the interference list is 
repeated back, the participant is asked to recall as many words from the first list that 
they can. Lastly, a checklist is provided with words from the first list, the 
interference list, and words on neither list. Participants are instructed to indicate 
which words were on the first list but not the second by placing a check mark next to 
the “first list” words. It has been found to be both reliable and valid (King, J.H., 
Gefeller, J.P. & Davis, H.P. 1998). 
Stroop Test 
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The Stroop test was administered via a computer program. It is designed to 
assess directed attention and attentional flexibility. It is administered in three 
segments. The first segment participants are instructed to name the color word, 
which appears in black text, which appears on the screen. For example, “Blue”. 
Participants press the space bar on the computer keyboard to progress as quickly as 
they can through the computer generated list of color words. The second segment is 
administered the same way, except colored “X”s appear on the screen and 
participants are instructed to name the color of the “X”s as quickly as possible. The 
third and final segment is color words written in a different color than the word 
written. For example, the word on the screen is “Blue” but it is written in the color 
yellow. Participants are instructed to name the color the word is written in, and not 
the word written. This last test provides a measure of processing speed in the face of 
a distracter and of attentional function. It has been found to be both a reliable and 
valid measure of these constructs (Koch, K, 2003). Processing speed and interference 
were also calculated based on the results of the three Stroop test segments. 
Processing speed was generated by adding the scores obtained from the Stroop color 
naming task and the word naming task (where each score indicates the total number 
of colors or words named correctly in the allotted 60 seconds per trial). This 
technique has been determined to be an advanced and accurate way to examine 
processing speed (Denney, D. & Lynch, S.,  2008). Interference was calculated by 
regressing the Stroop color-word naming score on the color naming score, and thus 
obtaining a residual score for each participant, and then adding the overall group 
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mean from the Stroop color-word naming test to the participants’ residual score 
(Denney, D. & Lynch, S., 2008). 
 
Mood 
Beck Depression Inventory-II 
 A Beck Depression Inventory-II (BDI-II) (Beck, Steer, and Brown, 1996) 
was administered to subjects upon first evaluation in the laboratory and upon the last 
day of the study. It is a 21-item self-report measure of depressive symptomatology 
(see appendix). Participants indicate how much they agree with a statement 
regarding a depressive symptom. A high score on the BDI-II is correlated with 
endorsing more depressive symptomatology than a lower score. The Beck 
Depression Inventory-II has been found to be both a reliable and valid measurement 
of depressive symptoms (Longwell, 2005; Beck, Steer, et al, 1996).   
Data Analyses 
 Primary study hypotheses regarding between-group differences on 
actigraphy-derived sleep measures as well as subjective sleep measures (PSQI, NSF 
Sleep Diary) and cognitive measures were tested by means of 2-by-2 multi-factorial 
analysis of variance.  Sleep data was averaged over the 7 nights of subjective and 
objective measures of sleep to produce aggregated scores on all sleep measures, 
taking into account the variation of sleep processes over the 7 day period. Observed 
time by treatment interaction effects were further examined by means of one-way 
analyses of covariance (using pre-treatment score as the covariate and post-treatment 
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score as the dependent variable) and paired-samples t-tests within each treatment 
group. An alpha level of .05 was used to determine statistical significance in all 
analyses. Twenty-eight individuals participated in this study, however, one 
participant was simultaneously engaged in another sleep intervention and that 
participant’s data was removed due to the nature of the secondary sleep intervention. 
 
Results 
The treatment and control groups were compared in terms of potential 
confounding variables; namely age, body mass index, gender, and minority status. 
There were no significant differences between the treatment and control groups on 
any of these demographic variables (see Table 1 and Table 2). 
Treatment and control groups were also compared at baseline, using 
independent samples t-tests, on the study’s outcome variables of interest: self-report 
measures of sleep disturbance (PSQI) and depressive symptomatology (BDI-II), 
sleep-diary and actigraphy measures of sleep efficiency, sleep onset latency, sleep 
wakening, and total sleep time, and four cognitive tasks (Letter-Number Sequencing, 
Rey Auditory and Verbal Learning Task, Stroop, and Trails A and B). The results of 
these tests can be found on Table 3, Table 4, and Table 5. The means and standard 
deviations for the adherence variable can be found in Table 2. No significant 
differences were observed on any of these baseline variables between groups. 
An adherence variable was also calculated based on the percentage of 
assigned pills that the participant reported having consumed. There was no 
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significant difference between groups regarding self-reported adherence to the 
treatment regiment. The means and standard deviations for the adherence variable 
can also be found in Table 2. 
In order to test for treatment effects on the outcome variables of interest, a set 
of 2x2 mixed factorial analyses of variance was conducted, with pre- and post-
treatment measures for each variable. These analyses allow for a test of the main 
effects of time (significant pre-post improvements) as well as a time-by-treatment 
interaction effect, which indicate between-group differences in the effect of 
treatment.  
Among measures of sleep (objective and subjective) there were no significant 
time-by-treatment interaction effects, a finding which indicates no substantial 
difference in improvement over time between the two groups. However, significant 
main effects for time were observed on 3 self-report (sleep diary) measures of sleep: 
sleep latency (pre-treatment mean= 31.634, standard error= 3.279; post-treatment 
mean= 21.458, standard error= 2.593, F(1,23)=10.811, p=.003), estimated total sleep 
time (pre-treatment mean= 439.800, standard error= 12.761; post-treatment mean= 
474.988, standard error= 13.783, F(1,23)=8.817, p=.007), and number of awakenings 
(pre-treatment mean= 2.038, standard error= .269; post-treatment mean= 1.086, 
standard error= .165, F(1,23)=13.392, p=.001). Likewise, there was no significant 
time-by-treatment interaction observed for the PSQI, but a significant main effect for 
time (pre-treatment mean= 10.309, standard error= .676; post-treatment mean= 
7.512, standard error= .567, F(1,24)=21.285, p<.001). There were no significant 
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main effects for group on any study sleep measures, including the PSQI, nor was 
there significant main effect or interaction for the BDI-II score. 
With respect to cognitive measures, one significant time-by-treatment 
interaction effect was observed; specifically, it occurred on the Stroop processing 
speed measure (F(1,18)=5.134, p=.036). As shown in Figure 1, the treatment group 
showed a substantial trend toward an increase in processing speed from pre- to post-
treatment (pre-treatment mean= 157.123, s.d.= 10.650; post-treatment mean= 
175.250, s.d.= 12.318, t= -2.29, p=.056). The control group also experienced a slight 
pre-post increase in processing speed, but it was not statistically significant (pre-
treatment mean= 145.667, standard error= 8.696; post-treatment mean= 147.083, 
standard error= 10.058, t= -.472, p=.646). In order to better account for the potential 
influence of baseline Stroop performance on the post-treatment outcome measure, an 
analysis of covariance was conducted, with pre-treatment Stroop score used as a 
covariate. The treatment group still performed significantly better than the control 
group (F(1, 20)= 4.52, p=.048, partial eta2=.210) when covarying for baseline score. 
There was also a significant main effect of time on the Stroop processing speed 
measure (pre-treatment mean= 151.396, standard error= 6.875; post-treatment 
mean= 161.167, standard error= 7.951, F(1,18)=7.023, p=.016). This is suggestive of 
an increase in processing speed. 
There was also a significant main effect of time on all 3 components of the 
RAVLT: immediate recall (pre-treatment mean= 8.588, standard error= .543; post-
treatment mean= 9.964, standard error= .510, F(1,24)=7.460, p=.012), delayed recall 
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(pre-treatment mean= 5.705, standard error= .691; post-treatment mean= 7.481, 
standard error= .719, F(1,23)=10.632, p=.003), and recognition (pre-treatment 
mean= 9.282, standard error= .639; post-treatment mean= 10.370, standard error= 
.440, F(1,24)=5.156, p=.032). No other main effects or interaction effects were 





This investigation represents the first reported placebo-controlled trial of the 
effect of omega-3 fatty acid supplementation on sleep disturbance. Among a group 
of 27 college undergraduates with self-reported symptoms of sleep disturbance, no 
specific beneficial effects of omega-3 ingestion on sleep quality or quantity were 
observed. Specifically, there were no significant differences in outcome between the 
omega-3 and placebo (vitamin E) groups on any of the objective (Actigraph) or 
subjective (sleep diary and PSQI) sleep measures of sleep efficiency, sleep latency, 
awakenings, total sleep time, or depressive symptomatology.  
There were, however, significant pre-post improvements in sleep observed in 
both groups, as indicated by four self-report measures. Self-reported measures of 
sleep latency decreased by approximately 67%, awakenings decreased by 
approximately 53%, and total sleep time increased by 7%. Also, the total score on 
the PSQI self-report sleep measure substantially improved in both treatment groups. 
These self-reported improvements appear consistent with placebo-like positive 
expectancy effects among participants in both treatment conditions- a hypothesis 
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supported by the fact that no significant improvements in sleep were observed on any 
of the study’s objective, Actigraphy-based measures. Presumably, if significant 
improvements in sleep quality and quantity had actually occurred, this would have 
been evident on both objective and subjective study measures. 
Among study cognitive measures, however, one significant between-group 
difference was observed. Specifically, on a component of the Stroop test that 
measures processing speed, participants receiving the omega-3 supplement were 
found to be significantly faster at post-treatment than they had been at baseline (pre-
treatment). This finding is consistent with some previously published reports which 
have also found omega-3 supplementation to enhance various cognitive processes, 
including processing speed (Kalmijn, et. al., 2004; Kalmijn, 2000, Kalmijn and 
Launer, 1997). However, this particular study finding should be interpreted with 
caution, given that the Stroop task was only completed by 20 study participants, only 
8 of whom were in the omega-3 condition. Moreover, there was no observed effect 
of omega-3 supplementation on two other study measures of processing speed (Trails 
A and B).  
Research investigating the relationship between Alzheimer’s disease and 
inflammation has found that inflammatory processes are involved in the 
pathogenesis of the disorder’s characteristic cognitive decline (Kalmijn, et.al, 2004). 
Related research has found that omega-3 supplementation and fish consumption are 
associated with decreased cognitive decline in Alzheimer’s patients (Kalmijn, et.al, 
2004). This was predominantly displayed in measures of processing speed. The 
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supported hypothesis is that omega-3’s affect speed of cognition through the 
inflammatory mechanism because they decrease the inflammation commonly 
associated with cognitive decline (Kalmijn, et.al., 2004). 
A main effect of time was also observed with all 3 components of the 
RAVLT. Performance on immediate recall, delayed recall, and recognition of 
presented stimuli improved over time for both treatment conditions. It is possible that 
this improvement over time- with an absence of between-group-differences- is due to 
practice effects. Several participants remarked that they remembered words from the 
initial administration of the RAVLT on their post treatment assessment. No other 
cognitive effects of omega-3 supplementation were found on the other cognitive tests 
included in the study.  
If the principal study findings- i.e., no specific benefit of omega-3 
supplementation regarding sleep- are replicated by other investigators, this would 
provide valuable information of conceptual and practical clinical utility. At a 
theoretical level, it could indicate less support for the hypothesized role of 
inflammation and hyperactivation of the HPA axis in sleep disturbance. Given that 
dietary omega-3 fatty acids promote decreased inflammation, which should in turn 
lead to decreased HPA axis hyperactivity, these results, if replicated, would suggest 
the likelihood of other factors contributing to sleep disturbance beyond merely 
inflammation and HPA axis hyperactivity.  
Clinically, these results, if replicated, also indicate that omega-3 fatty acid is 
not an effective treatment for at least some forms of sleep disturbance- specifically, 
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problems with sleep efficiency, sleep onset, and frequent awakening. It would 
remain to be shown whether or not such supplementation would be of benefit for 
sleep problems among depressed individuals- a population shown in previous 
investigations to experience an overall reduction in depressive symptomatology with 
omega-3 supplementation.  
There may be several factors that contributed to the study’s largely null 
results. First, the literature on which this study was based had focused on the 
treatment of depression and HPA-axis hyperactivity, while the study sample 
comprised a non-clinical group of non-depressed individuals. It is possible that those 
who suffer from depression, and commensurate HPA-axis hyperactivity, may find 
sleep benefits from omega-3 fatty acid supplementation more so than the participants 
in this study. According to the BDI-II scores obtained before and after the 
intervention, the great majority of participants scored in the low range, which 
indicates that they were not experiencing clinical levels of depressive 
symptomatology.  
Also, this study only used one particular dosage combination of the two 
prominent long-chain of omega-3 fatty acids: 1000mg of EPA and 500 mg of DHA 
daily. It may be that higher dosages could prove to be more effective. Clinical 
studies investigating other disorders, such as depression and schizophrenia have 
found that a higher omega-3 dosage may actually be related to increased symptom 
reduction (Peet and Stokes, 2005). Also, it is possible that a different ration of EPA 
and DHA may be more beneficial for reduction in sleep disorder symptoms. This 
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investigation only used one particular ration of EPA/DHA (2:1) that has been found 
beneficial in those with depressive symptoms.  
This study also neglected to look at blood plasma ratios of omega-6 to 
omega-3 fatty acids. It has been hypothesized that high omega-6 ratios common 
among those who consume the typical American diet, may require higher levels of 
omega-3 fatty acids to counter the deleterious effects of pro-inflammatory omega-6 
fatty acids (Hibbeln, et al., 2006).  
Although all but one study subject scored above a “5” on the baseline PSQI, 
indicating a high probability of at least some significant sleep difficulties, the sample 
was not formally screened for clinically significant experiences of insomnia. It may 
be that omega-3 fatty acid supplementation only works to reduce symptoms of 
insomnia in a more severely sleep-disordered population. It is possible, in other 
words, that the study’s  null results are related to its truncated range of sleep 
difficulties, and that participants’ sleep disturbances were not clinically significant 
enough to permit measurement of intervention-related change.  
It is also likely that some participants in this college sample experienced 
sleep difficulties due to lifestyle factors instead of chronic or prolonged biologically 
based insomnia. A qualitative review of participant sleep diaries revealed many sleep 
disruptions due to environmental irregularities, such as roommate noise and 
uncomfortable room temperature. These environmentally-based disruptions are 
different from the disturbances that would be expected in a population experiencing 
insomnia for biologically-based reasons. It may be, therefore, that omega-3 fatty acid 
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is helpful in addressing some sleep difficulties of an organic nature (like HPA axis 
dysregulation), as opposed to the sleep-related difficulties of an environmental nature 
that appear to have been commonplace among study participants. Also, insomnia is a 
heterogeneous disorder in which there are multiple reasons for poor quality and 
quantity of sleep. Some forms of insomnia are easily measured scientifically, while 
others are less measurable. Insomnia that takes on a more psycho-physiological 
pattern may be less observable by scientific measurement, yet participants still may 
report feeling tired or that their sleep isn’t restful and may meet criteria for clinical 
insomnia. However, the scientific measurement of sleep quality and quantity may not 
adequately display their sleep disturbances or poor quality of sleep. It is possible that 
this sample of college-age students is experiencing a clinical level of insomnia that 
may be more psycho-physiological in nature and thus less easily measured.  
There are also several prominent study limitations worth noting. First, this 
study employed a relatively small sample size, with only 27 total participants- and 
only 12 in the treatment condition. Thus, the study suffered from low statistical 
power to detect anything but large-magnitude effects; it is possible, therefore, that a 
larger sample size would have yielded different results. This study was also limited 
by the truncated age range of participants. It is possible that supplementation with a 
wider age range may reveal important information about effectiveness at different 
ages. Also, there was no external measure of participant adherence to the 
supplementation protocol, and the investigator could only rely on self-report of 
adherence. Therefore, it is not known if the participants actually complied with the 
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entire treatment protocol. Other measures of adherence, such as blood samples 
testing for levels of circulating omega-3 fatty acids, could substantially improve 
confidence in the measurement of adherence. Also, this investigation did not control 
for participant medication use or other substance use- e.g., stimulants, 
antidepressants, alcohol- that have an established potential to affect sleep quality and 
quantity. This study also did not directly measure the use of prescription sleep aids. 
As mentioned previously, participants in this study were not formally screened for 
diagnostic-level insomnia, nor were they categorized by the type of sleep disturbance 
they were experiencing, and it cannot be ruled out that they utilized sleep medication 
while participating in the study. 
 
Directions for Future Research 
As noted, future research is needed to examine the use of omega-3 fatty acid 
supplementation on insomnia and other sleep problems in a clinically depressed 
population. Also, examination of changes in sleep using a higher dosage or longer 
duration of omega-3 fatty acid supplementation may prove influential on sleep 
processes. Research should also be conducted to assess for an optimal ratio of 
omega-6 to omega-3 fatty acids that may reduce symptoms of insomnia. 
It would also be beneficial to see future investigations that utilize a non-
college sample in order to attempt to control for unique environmental influences on 
sleep that characterize college populations. Likewise, it would be wise to measure 
and control for prescription stimulant and sedative medication use in future studies. 
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Also, it is suggested that future research focus on using participants with a high 
likelihood of  biological underpinnings for their sleep disturbance, as it is 
hypothesized that this population, as opposed to a non-clinical college population, 
would evidence a favorable response to an omega-3 intervention. 
Also, given the significant finding with respect to improvement in cognitive 
processing speed, a replication study is warranted, as is future research regarding the 
benefits of increased dosage. Investigations using omega-3 supplementation for the 
purpose of examining cognitive processing speed should focus on not only dosage 
effects, but also type of omega-3, and duration of supplementation that is most likely 
to produce increases in cognitive performance. Strong research investigating the 
possible benefits of omega-3 supplementation on cognitive processing speed should 
include multiple methods of measuring processing speed, given that participants in 
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Gender (M/F)              M (SD) 13/14 6/6 7/8 
Age                              M (SD) 19.89 (2.81) 19.91 (2.68) 19.87 (3.00) 
Minority (Y/N)            M (SD) 6/21 4/8 2/13 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1.) Stroop Processing Speed 
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